Drug
Dnl921
Dnl921: highest development phase Phase 1, developed by Denali Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL921 NCT07758595 | Phase 1 | Alzheimer's Disease |
Latest
No recent events.
Follow Dnl921 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.